Patients having chronic lymphocytic leukemia (CLL) are at increased risk fo
r infectious morbidity and mortality. The predisposition to infections in C
LL patients has many components; including both immunodeficiency related to
the leukemia itself (humoral and cellular immune dysfunction) and the resu
lts of cumulative immunosuppression related to CLL treatment. The risk of i
nfectious complications increases with the duration of CLL, reflecting the
natural history of the disease and the cumulative immunosuppression related
to its treatment. Hence, in early, untreated CLL, the infectious risk is m
ainly related to hypogammaglobulinemia, and infections by encapsulated bact
eria are common, However, in patients having advanced CLL, particularly tho
se who receive the newer purine analogues, neutropenia and defects in cell-
mediated immunity appear to be the major predisposing factors. An expanded
spectrum of pathogens, including opportunistic fungi, Pneumocystis carinii,
Listeria monocytogenes, mycobacteria, and herpesviruses, are seen, in that
setting. The changing spectrum of infections in this latter group of patie
nts mandates a newer approach to prophylaxis and therapy.